Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv Inc (NOTV) provides essential nonclinical research services and analytical solutions for pharmaceutical and medical device development. This news hub offers investors and industry professionals centralized access to official updates and strategic developments impacting the company's position in contract research organizations.
Track critical announcements including quarterly earnings reports, regulatory milestones, scientific partnerships, and operational expansions. Our curated collection ensures timely access to press releases covering drug discovery advancements, facility upgrades, and leadership changes.
Key updates feature developments from both business segments: Discovery & Safety Assessment services for preclinical research and Research Models & Services supporting biomedical studies. Stay informed about technological innovations in laboratory instrumentation and compliance achievements affecting therapeutic development pipelines.
Bookmark this page for verified updates on Inotiv's contributions to pharmaceutical research, including collaborations with biotech firms and regulatory submissions. Check regularly for objective reporting on operational developments that shape the CRO industry landscape.
Inotiv (NASDAQ: NOTV), a contract research organization focused on nonclinical and analytical drug discovery and development services, has scheduled its fiscal 2025 second quarter financial results announcement for Wednesday, May 7, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Participants can join via phone using the following numbers:
- Domestic: 1-800-245-3047
- International: 1-203-518-9765
- Conference ID: INOTIV
A live webcast will be available through the Investors section of Inotiv's website, with a replay accessible afterward at ir.inotiv.com/overview/default.aspx.
Inotiv (NOTV) reported Q1 FY2025 financial results showing an 11.5% revenue decline to $119.9 million compared to Q1 FY2024. The company experienced decreased revenue across both segments: Research Models & Services (RMS) declined 15.1% to $77.1 million, while Discovery & Safety Assessment (DSA) fell 4.2% to $42.8 million.
The company reported a net loss of $27.6 million (23.0% of revenue) compared to $15.8 million loss in Q1 FY2024. Adjusted EBITDA decreased to $2.6 million (2.2% of revenue) from $9.6 million in the prior year. The company strengthened its liquidity position by raising $27.5 million through a public offering of 6.9 million common shares at $4.25 per share.
DSA backlog stood at $130.4 million with a book-to-bill ratio of 1.01x. The company expects annual cost savings of $4.0-$5.0 million following the completion of its North American RMS site optimization plan.
Inotiv (NASDAQ: NOTV), a contract research organization focused on nonclinical and analytical drug discovery services, has scheduled its fiscal 2025 first quarter financial results announcement for Wednesday, February 5, 2025, after market close. The results will cover the period ended December 31, 2024.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Participants can join via phone using the following numbers: 1-800-579-2543 (Domestic) or 1-785-424-1789 (International), with Conference ID: INOTIV. A live webcast will be available through the company's Investors section website, with a replay accessible afterward.
Inotiv (NOTV) has completed an equity offering, raising approximately $3.6 million in net proceeds through the issuance of 900,000 additional common shares at $4.25 per share. The offering, which closed on December 30, 2024, was executed in connection with a previously announced underwritten public offering. Lake Street Capital Markets acted as the sole book-running manager. The company plans to utilize the proceeds for working capital, capital expenditures, and general corporate purposes. The offering was conducted under a shelf registration statement that became effective on August 31, 2022.
Inotiv (NOTV) has successfully completed an equity offering, raising approximately $24.0 million in net proceeds through the sale of 6,000,000 common shares at $4.25 per share. The offering closed on December 19, 2024, with Lake Street Capital Markets acting as the sole book-running manager. The company has granted underwriters an option to purchase up to 900,000 additional shares until January 17, 2025.
The proceeds will be used for working capital, capital expenditures, and general corporate purposes. CEO Robert Leasure Jr. emphasized that this additional liquidity strengthens the company's balance sheet and enhances financial flexibility, supporting ongoing strategic initiatives aimed at improving customer experience and shareholder value.
Inotiv (NOTV), a contract research organization focused on drug discovery services and research models, has announced the pricing of its public offering of 6,000,000 common shares at $4.25 per share. The company has granted underwriters a 30-day option to purchase up to an additional 900,000 shares at the same price.
The offering is expected to close on December 19, 2024. Lake Street Capital Markets is serving as the sole book-running manager. Inotiv plans to use the net proceeds for working capital, capital expenditures, and general corporate purposes.
Inotiv (NOTV), a contract research organization focused on nonclinical and analytical drug discovery services, has announced a proposed underwritten public offering of common shares. The company will offer all shares and plans to grant underwriters a 30-day option to purchase up to 15% additional shares. Lake Street Capital Markets is serving as the sole book-running manager for the offering.
The offering is subject to market conditions, with no guarantee of completion or final terms. It will be conducted under a shelf registration statement on Form S-3 that was declared effective by the SEC on August 31, 2022.
Inotiv (NOTV) reported Q4 FY2024 financial results showing revenue decline of 7.3% to $130.4 million compared to Q4 FY2023. Full-year fiscal 2024 revenue decreased 14.3% to $490.7 million. The company experienced declines in both Discovery & Safety Assessment (DSA) and Research Models & Services (RMS) segments.
Q4 FY2024 consolidated net loss was $18.9 million, or 14.5% of total revenue. The company enhanced liquidity through issuance of Second Lien Notes worth $22.6 million and obtained credit agreement amendments. The DSA backlog stood at $129.9 million as of September 30, 2024.
The company plans further integration and cost reduction initiatives for 2025, projecting $4.0-5.0 million in operating expense reductions through RMS facility optimization, with benefits expected in fiscal 2026.
Inotiv has been ranked 138th on the 2024 Deloitte Technology Fast 500™, marking its second consecutive year on the prestigious list. The company achieved an impressive 847% revenue growth over the past five years. As a full-service CRO and research model provider, Inotiv's growth strategy has focused on strategic acquisitions, integration, and streamlining operations while prioritizing customer needs. The company previously ranked 127th in 2023. The 2024 Technology Fast 500 companies demonstrated revenue growth ranging from 201% to 153,625%, with an average growth rate of 1,981% and median growth rate of 460%.
Inotiv (Nasdaq: NOTV), a contract research organization focused on nonclinical and analytical drug discovery services, has scheduled its fiscal 2024 fourth quarter and full year financial results announcement for Tuesday, December 3, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can participate via phone (1-800-267-6316 Domestic, 1-203-518-9783 International) or access the webcast through the company's investor relations website.
